Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024
Leader in Women’s Health Will Unveil Groundbreaking Innovations With a Focus on Imaging Solutions and Artificial Intelligence
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125586668/en/
Experience the cutting-edge Envision™ Mammography Platform (Graphic: Business Wire)
For the first time, attendees can experience the cutting-edge Envision™ Mammography Platform, which offers patients a high-speed Hologic 3D™ mammogram with an industry-leading 2.5-second scan time.1* This next-generation technology provides a more comfortable exam with tilt positioning, adapting to patients rather than the other way around.2 As the first FDA-approved mammography technology of its kind,3 the Envision platform enhances the detection of subtle objects, minimizes focal spot blur and improves 3D image sharpness.4,5,6*
“There is tremendous excitement surrounding our latest breast health innovations, and our team is looking forward to showcasing the many ways we’re advancing solutions across the breast health continuum at this year’s RSNA,” said
Further demonstrating its leadership in breast imaging AI, Hologic will also introduce its next-generation Genius AI® Detection PRO solution for use in
- A deep-learning 2D and 3D algorithm that improves specificity by using a patient’s prior exam in the current exam’s analysis.
- Intuitive 1-10 case and lesion scoring and pre-populated exam reports designed to accelerate image review and save radiologists’ valuable time.
- An all-in-one interface that conveniently includes deep-learning breast densityscoring along with key patient and mammogram quality information, designed to support radiologists at every step of the reading workflow.
“With Genius AI Detection PRO, Hologic continues to lead the way in innovation for AI in breast imaging and cancer detection,” said Anderson. “By harnessing the latest advances in artificial intelligence and transformative workflow features, we continue to push the boundaries of science to revolutionize mammography and the future of women’s healthcare.”
On
In the South Hall, Booth #1919 at
Additionally, Hologic will host several workshops including:
-
Navigating Breast Localization: From Imaging to Surgery
Sunday, Dec. 1 :11:45 a.m.-12:45 p.m. CST (Room S502)
A panel discussion aiming to foster collaboration between radiologists and surgeons and discuss the latest advancements and best practices in breast localization to improve patient care and outcomes.
-
Enhancing Breast Cancer Detection: The Role of AI in Mammography
Tuesday, Dec. 3 :12-1 p.m. CST (Room S502)
This presentation will delve into the transformative impact of AI on breast cancer detection. Speakers will discuss how AI technologies, particularly machine learning and deep learning algorithms, are enhancing the accuracy, speed and reliability of breast cancer screening processes.
-
Innovative Advancements in Breast Cancer Screening: The Role of Contrast-Enhanced Mammography
Wednesday, Dec. 4 :12-1 p.m. CST (Room S502)
This presentation will explore contrast-enhanced mammography (CEM) in breast cancer detection. Speakers will talk about how CEM enhances traditional mammography by providing more detailed and accurate imaging, leading to improved diagnostic outcomes.
Finally, Hologic is proud to announce it was recently awarded the Excellence in Imaging Informatics Award by the American
To learn more about Hologic’s presence at RSNA 2024, please visit Hologic.com/RSNA.
About
Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
Hologic, The Science of Sure, Dimensions, Envision, Genius AI, Genius AI Detection PRO, Genius AI Detection 2.0, I-View, LOCalizer, Magseed, Magtrace and Sentimag are trademarks and/or registered trademarks of
References
* |
|
Compared to the 3DimensionsTM Mammography System (3.7sec). DHM-05051_002. |
1 |
|
Hologic data on file: VER-12082 (1.0). |
2 |
|
Hologic data on file: DHM-16430. |
3 |
|
FDA PMA Approval P080003/S009, 2024. |
4 |
|
Hologic data on file: DHM-16158. |
5 |
|
Hologic data on file: DHM-14517. |
6 |
|
Smith, A. Tushita, P. Improving Tomosynthesis Image Quality using Advanced X-ray Technologies, Hologic WP-00300 (2024). |
7 |
|
S. Pacilè, et al. (2024). Evaluation of a multi-instant multi-modal AI system supporting interpretive and noninterpretive functions. Accepted for publication in the |
8 |
|
K240301 510(k) summary distributed by |
9 |
|
Kshirsagar A, Smith, A. Reducing Bias in Breast Cancer Detection AI: Assessing the performance of Hologic’s Genius AI Detection Solution across different races and ethnicities, Hologic WP-00297 (2024). |
SOURCE:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241125586668/en/
Media Contact
Senior Director, Corporate Communications
+1 508.263.8654
bridget.perry@hologic.com
Investor Contact
Vice President, Investor Relations
+1 858.410.8514
ryan.simon@hologic.com
Source: